CT-03
Chemotherapy-resistant Acute Myeloid Leukaemia (AML) and other liquid/solid tumors
Preclinical / Phase I PrepActive
Key Facts
Indication
Chemotherapy-resistant Acute Myeloid Leukaemia (AML) and other liquid/solid tumors
Phase
Preclinical / Phase I Prep
Status
Active
Company
About Captor Therapeutics
Captor Therapeutics is a clinical-stage biotech focused on unlocking the 'undruggable' proteome through targeted protein degradation. Founded in 2017 and publicly listed in Warsaw, the company has validated its scientific approach by securing substantial EU and Polish grant funding and advancing its lead MCL-1 degrader, CT-03, toward clinical trials. Its strategy combines world-class R&D in Wroclaw with strategic business development in Basel to build a leading European TPD franchise.
View full company profile